In a patient with amyotrophic lateral sclerosis, should a depolarizing muscle relaxant be used and what non‑depolarizing agents and dosing are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amyotrophic Lateral Sclerosis and Muscle Relaxants

Depolarizing muscle relaxants (succinylcholine/suxamethonium) should be absolutely avoided in patients with ALS due to the risk of life-threatening hyperkalemia from denervated muscle. Use non-depolarizing agents instead, with careful dose reduction and mandatory neuromuscular monitoring.

Depolarizing Agents: Contraindicated

Patients with ALS have denervated, hypersensitive muscle tissue that expresses extrajunctional acetylcholine receptors throughout the muscle membrane. When exposed to depolarizing agents like succinylcholine, this causes:

  • Massive potassium release from muscle cells
  • Potentially fatal hyperkalemic cardiac arrest
  • Risk similar to other denervation states (burns, spinal cord injury)

This is a hard contraindication 1. The mechanism is well-established in neuromuscular disease states, and the mortality risk is unacceptable.

Non-Depolarizing Agents: Recommended with Caution

Agent Selection

Rocuronium is the preferred non-depolarizing agent because it can be reliably reversed with sugammadex, though significant caveats exist (see below) 2.

Alternative agents include:

  • Atracurium
  • Cisatracurium
  • Vecuronium

Critical Dosing Principles

Reduce initial doses by 50-75% compared to standard dosing due to markedly increased sensitivity in ALS patients. ALS patients demonstrate:

  • Heightened sensitivity to non-depolarizing agents
  • Prolonged duration of action
  • Risk of incomplete reversal even with standard reversal doses

Start with test doses: For rocuronium, consider 0.3-0.4 mg/kg (vs. standard 0.6 mg/kg) or even lower (0.52 mg/kg successfully used in case reports) 3, 4.

Mandatory Neuromuscular Monitoring

Quantitative train-of-four (TOF) monitoring is absolutely essential - not optional - throughout the entire perioperative period 2:

  • Monitor continuously from induction through full recovery
  • Do not rely on clinical assessment alone
  • Ensure TOF ratio ≥0.9 before extubation
  • Continue monitoring post-reversal for recurarization

Reversal Strategy

For Rocuronium/Vecuronium: Sugammadex

Sugammadex is the preferred reversal agent for steroidal muscle relaxants in ALS patients, but with critical warnings 2:

Dosing based on depth of blockade:

  • Very moderate block (TOF ratio 0.5): 0.22 mg/kg
  • Moderate block (TOF count = 4): 1.0-2.0 mg/kg
  • Deep block (TOF count = 2): 2.0-4.0 mg/kg
  • Very deep block (PTC 1-2): 4.0 mg/kg
  • Immediate reversal: 8.0 mg/kg

Critical Caveat: Incomplete Reversal Risk

Case reports document incomplete reversal and recurarization in ALS patients even with appropriate sugammadex dosing 5. In one case:

  • 4 mg/kg sugammadex initially achieved TOF ratio 54%
  • Patient then re-paralyzed (TOF count dropped to 1-3, tidal volume <100 mL)
  • Required additional 50 mg sugammadex
  • Delayed full recovery

This means:

  • Standard sugammadex doses may be insufficient
  • Have additional sugammadex immediately available
  • Monitor for at least 30-60 minutes post-reversal
  • Consider ICU admission for continued monitoring
  • Do NOT extubate until TOF ratio definitively ≥0.9 and stable

For Atracurium/Cisatracurium: Neostigmine

If using benzylisoquinolinium agents, reversal with neostigmine 2:

  • Only reverse when TOF count = 4 (wait if fewer responses)
  • Dose: 0.04 mg/kg neostigmine + 0.02 mg/kg atropine
  • Expect 10-20 minutes to achieve TOF ratio ≥0.9
  • Continue monitoring throughout recovery period

Alternative Approach: Avoid Muscle Relaxants Entirely

Consider deep inhalational anesthesia without muscle relaxants when feasible 6:

  • High-dose propofol (3 mg/kg) + sevoflurane (5%) for intubation
  • Maintain with 2-3% sevoflurane for surgical relaxation
  • Eliminates reversal concerns entirely
  • Suitable for shorter procedures where profound relaxation not essential

Postoperative Management

Plan for extended monitoring and respiratory support:

  • ICU admission strongly recommended
  • Assisted ventilation may be needed despite "adequate" reversal
  • ALS patients have baseline respiratory compromise
  • Risk of aspiration pneumonia is elevated (documented in case reports) 5
  • Have non-invasive ventilation immediately available

Key Pitfalls to Avoid

  1. Never use succinylcholine - this cannot be overstated
  2. Never use standard muscle relaxant doses - always reduce significantly
  3. Never rely on clinical assessment alone - quantitative monitoring mandatory
  4. Never assume standard reversal doses are adequate - have extra sugammadex ready
  5. Never extubate without confirmed TOF ratio ≥0.9 - recurarization is documented
  6. Never discharge to floor - these patients need ICU-level monitoring

The evidence base consists primarily of case reports and expert consensus 3, 5, 4, 6, with general muscle relaxant guidelines 2 providing the reversal framework. The 2020 Anaesthesia guidelines provide the most comprehensive and recent guidance on reversal strategies, though they don't specifically address ALS populations.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.